Tengion (TNGN) is Making Waves in a Regenerative Medicine Waters: GERN, CYTX

When investors consider of ‘regenerative medicine stocks’, they tend to consider of names like Geron Corporation (NASDAQ:GERN) or Cytori Therapeutics Inc. (NASDAQ:CYTX). So, when small $14 million Tengion, Inc. (NASDAQ:TNGN) started creation some large waves final week, it held some investors – and some of a company’s bigger competitors – off guard. That can be a good thing though, quite if a intrusion puts an engaging event on a table.

The regenerative medicine attention is still gelling, nonetheless it has been effectively tangible as a use of regulating a patients possess cells (specifically, a DNA inside them) to grow or re-grow shop-worn tissue.

Cytori Therapeutics is pushing some quarterly revenue, nonetheless it’s mostly in a RD stages operative some-more on a record to use a grounds than a treatments themselves. To date, a bulk of a concentration has been on heart illness and reconstructive surgery; CYTX is sponsoring a hearing in Europe for any of those aim markets. The former is to weigh a use of adipose-derived branch and regenerative cells (ADRCs) to provide strident heart attacks and ongoing coronary artery disease. The latter is exam a routine in breast reformation after lumpectomy for breast cancer.

Geron Corporation is putting many of a eggs in a cancer basket. GRN163L (pr Imetelsat) and GRN1005 are both in clinical trials (Phase II) right now, and both are formed on 3 law core technologies: telomerase, tellurian rudimentary branch cells and chief transfer. In layman’s terms, GERN is regulating ‘working’ DNA from tellurian rudimentary branch cells to correct ‘non-working’ patient’s cells.

It’s complicated things to be sure, and Cytori and Geron are positively not alone in a regenerative medicine race. Tengion, Inc. wasn’t a aspirant possibly approaching to b e saying anytime shortly though.

So what is it about TNGN that done it value 77% some-more currently than what it was value dual weeks ago? For that matter, what is it about Tengion caused buyers to dip adult some-more than 700,000 shares in what will me a multi-month record volume day today?

It wasn’t news. The association hasn’t had any concrete news given Dec 13th when it announced new information would be presented during a annual TERMIS meeting, and a batch didn’t stop a decrease and start to convene until a 22nd of December.

Rather, a usually trustworthy reason for a remarkable reconstruction of TNGN is – wait for it – a marketplace has motionless to tumble in adore with a grounds again. Don’t laugh; it happens.

Tengion, Incorporated’s explain to celebrity in a universe of regenerative therapy is correct of a Neo-Urinary Conduit, or NUC. Its investigate to date has shown successful use of adipose-derived well-spoken flesh cells to provide bladder cancer patients… nonetheless not humans, yet. Pre-clinical studies being conducted now have shown success in rats, and a company’s identical line of contrast has shown guarantee in dog kidneys. Though a commercial product is years off, these early formula uncover a good understanding of promise.

All of that being said, while Tengion, Inc. is staid to enhance a fan bottom now, a work also legitimizes a regenerative therapy transformation as a whole… some much-needed assistance too, after a open balked during a thought itself when realizing it embody use of argumentative rudimentary branch cells (which usually a handful of these companies indeed utilize). Perhaps that flourishing group-wide toleration will bear some-more fruit for TNGN investors than a company’s RD will, during slightest for a foreseeable future.

Either way, Tengion has announced a participation with some management (finally), and while leaders like Geron and Cytori Therapeutics have small to fear yet, fans of regenerative medicine bonds do need to put TNGN on their watchlists. It’s singular hankie expansion height has applications in urologic, renal, gastrointestinal, and vascular diseases, only for starters.

Incoming search terms:

January 13, 2012 | Tags: | No Comments »
 
//======================================================================== //========================================================================